HALO
Halozyme Therapeutics Inc
NASDAQ: HALO · HEALTHCARE · BIOTECHNOLOGY
$63.06
-1.25% today
Updated 2026-04-29
Market cap
$7.47B
P/E ratio
24.63
P/S ratio
5.35x
EPS (TTM)
$2.56
Dividend yield
—
52W range
$48 – $82
Volume
1.6M
Halozyme Therapeutics Inc (HALO) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
7 of 8
Last 8 quarters
Avg EPS surprise
-15.6%
Last 4 quarters
Revenue YoY growth
+51.6%
Most recent quarter
EPS YoY growth
-119.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+0.9%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
+3.9%
2025-08-05
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-24 | $-0.24 | -112.6% | $70.64 | $70.35 | -0.4% |
| 2025-10-28 | $1.72 | +6.8% | $65.85 | $65.26 | -0.9% |
| 2025-08-05 | $1.54 | +25.2% | $59.99 | $62.32 | +3.9% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $1.90 | $-0.24 | -112.6% | $451.77M | +51.6% |
| 2025-09-30 | $1.61 | $1.72 | +6.8% | $354.26M | +22.1% |
| 2025-06-30 | $1.23 | $1.54 | +25.2% | $325.72M | +40.8% |
| 2025-03-31 | $0.94 | $1.11 | +18.1% | $264.86M | +35.2% |
| 2024-12-31 | $1.16 | $1.26 | +8.7% | $298.01M | +29.5% |
| 2024-09-30 | $0.98 | $1.27 | +29.6% | $290.08M | +34.3% |
| 2024-06-30 | $0.76 | $0.91 | +19.7% | $231.35M | +4.7% |
| 2024-03-31 | $0.70 | $0.79 | +12.9% | $195.88M | — |
| 2023-12-31 | $0.83 | $0.82 | -1.2% | $230.04M | — |
| 2023-09-30 | $0.71 | $0.75 | +5.6% | $216.03M | — |
| 2023-06-30 | $0.63 | $0.74 | +17.5% | $221.04M | — |
Frequently asked questions
Has Halozyme Therapeutics Inc beaten earnings estimates?
Halozyme Therapeutics Inc has beaten Wall Street EPS estimates in 7 of its last 8 quarterly reports, with an average EPS surprise of -15.6% over the last 4 quarters.
How does HALO stock react to earnings?
HALO stock has moved an average of +0.9% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Halozyme Therapeutics Inc's revenue growth rate?
Halozyme Therapeutics Inc reported year-over-year revenue growth of +51.6% in its most recent quarter, with EPS growing -119.0% year-over-year.